Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Altimmune Inc (ALT)
NASDAQ:ALT
Altimmune (ALT) Stock Price & Analysis
2,795 Followers
ALT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.09 - $14.84
Previous Close$6.28
Volume2.38M
Average Volume (3M)3.61M
Market Cap
$445.27M
Enterprise Value$263.24M
Total Cash (Recent Filing)$182.02M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Aug 08, 2024EPS Estimate
-$0.35Last Dividend Ex-Date
Feb 06, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-1.59
Shares Outstanding70,902,191
10 Day Avg. Volume3,573,195
30 Day Avg. Volume3,612,154
Standard Deviation0.56
R-Squared0.00008
Alpha0.11
Financial Highlights & Ratios
Price to Book (P/B)2.34
Price to Sales (P/S)90896.61
Price to Cash Flow (P/CF)-6.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue642.05
Enterprise Value/Gross Profit617.94
Enterprise Value/Ebitda-2.90
Forecast
1Y Price Target
$20.33Price Target Upside223.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Altimmune News
Bulls Say, Bears Say
Bulls Say
Clinical Trial DataThe new body composition data from the Phase 2 MOMENTUM trial show lean mass accounted for only 22% of weight lost in pemvidutide-treated patients — less lean mass lost than semaglutide and tirzepatide.
Lipid ReductionsThe company presented new lipid data showing significant reductions in small, dense LDL particles, LDL triglyceride content, and atherogenic lipid species that should translate to cardiovascular benefit over time.
NASH TreatmentSurvodutide showed the best NASH resolution rate seen at 83% and also hit statistical significance on fibrosis which differentiates the GLP-1/glucagon agonists from both the GLP-1 monotherapies and GLP-1/GIP agonists.
Bears Say
Drug TolerabilityLimited safety data from the NASH trial note survodutide appears to be harder to tolerate than pemvidutide.
Patient TolerabilitySurvodutide appears to be harder to tolerate than pemvidutide, with ~30% of survodutide patients in the prior Phase 2 obesity trial not able to get to a lower target dose and 29% discontinuing due to adverse effects.
Stock Price TargetThe new $24 price target ($25 previously) is primarily due to more potentially dilutive shares outstanding.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ALT FAQ
What was Altimmune Inc’s price range in the past 12 months?
Altimmune Inc lowest stock price was $2.09 and its highest was $14.84 in the past 12 months.
What is Altimmune Inc’s market cap?
Currently, no data Available
When is Altimmune Inc’s upcoming earnings report date?
Altimmune Inc’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were Altimmune Inc’s earnings last quarter?
Altimmune Inc released its earnings results on May 09, 2024. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.37 by $0.03.
Is Altimmune Inc overvalued?
According to Wall Street analysts Altimmune Inc’s price is currently Undervalued.
Does Altimmune Inc pay dividends?
Altimmune Inc pays a Notavailable dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune Inc dividends here
What is Altimmune Inc’s EPS estimate?
Altimmune Inc’s EPS estimate is -$0.35.
How many shares outstanding does Altimmune Inc have?
Altimmune Inc has 70,902,190 shares outstanding.
What happened to Altimmune Inc’s price movement after its last earnings report?
Altimmune Inc reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.37. Following the earnings report the stock price went up 7.821%.
Which hedge fund is a major shareholder of Altimmune Inc?
Among the largest hedge funds holding Altimmune Inc’s share is Farallon Capital Management, L.L.C.. It holds Altimmune Inc’s shares valued at 5M.
---
Altimmune Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.33 (223.73% Upside)
$20.33 (223.73% Upside)
Blogger Sentiment
Bullish
ALT Sentiment 97%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 484.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 7.8%
Last 30 Days ▲ 7.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
96.25%
12-Months-Change
Fundamentals
Return on Equity
-54.46%
Trailing 12-Months
Asset Growth
0.68%
Trailing 12-Months
Company Description
Altimmune Inc
The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.
---
ALT Earnings Call
Q1 2024
0:00 / 0:00
---
ALT Stock 12 Month Forecast
Average Price Target
$20.33
▲(223.73% Upside)
Technical Analysis
Best Analysts Covering ALT
1 Year
1 Year Success Rate
15/39 ratings generated profit
1 Year Average Return
+4.54%
reiterated a buy rating 28 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of +4.54% per trade.
---